Pharmaceutical company AcuCort has published its September 2026 newsletter. In the newsletter, the company highlights the scientific publications on Zeqmelit® and explains the importance of scientific publication for AcuCort’s continued development and international expansion.
Read the newsletter
https://bit.ly/4z4JUsY
Would you like to receive future newsletters directly in your inbox?
Sign up here:
https://www.acucort.se/EN/media/subscribe/
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.